List view / Grid view
6 October 2015 | By Victoria White
Results from a Phase III study show that Cotellic plus Zelboraf helped people with advanced melanoma live significantly longer compared to Zelboraf alone...
6 October 2015 | By Victoria White
Elbasvir/grazoprevir showed sustained virologic response in patients with chronic hepatitis C virus with advanced chronic kidney disease...
5 October 2015 | By Victoria White
The trial is a global study in patients with chronic plaque psoriasis to compare the safety, efficacy and immunogenicity of M923 with Humira...
5 October 2015 | By Victoria White
The Eluvia Stent System is an advanced treatment option for patients with narrowing or blockages in the superficial femoral artery or proximal popliteal artery...
5 October 2015 | By Victoria White
The combination is approved to reduce the risks of disease progression and hospitalisation for worsening PAH, and to improve exercise ability...
5 October 2015 | By Victoria White
Keytruda is now the first and only anti-PD-1 ((programmed death receptor-1) therapy approved for both squamous and non-squamous metastatic NSCLC...
2 October 2015 | By Victoria White
Through the Rimsa acquisition, Teva will become a leading pharmaceutical company in the second largest market in Latin America...
2 October 2015 | By Victoria White
Sandoz is seeking approval for all indications included in the label of etanercept which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
2 October 2015 | By Victoria White
Moxatag is a penicillin-class antibacterial indicated for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes...
2 October 2015 | By Victoria White
Raxone is also the first approved treatment for any mitochondrial disease, a therapeutic area which is in the focus of Santhera...
2 October 2015 | By Victoria White
Merck and DNAtrix will evaluate the efficacy and safety of DNX-2401 in combination with Keytruda in a Phase 2 study...
1 October 2015 | By Victoria White
The acquisition of Kythera adds Kybella, an injection for improvement in the appearance of moderate to severe submental fullness, to Allergan’s portfolio...
1 October 2015 | By Victoria White
Genzyme has elected to opt into the programme for development and potential future commercialisation of ALN-AT3 in territories outside of North America and Western Europe...
1 October 2015 | By Victoria White
The announcement marks the first and only FDA approval of a Regimen of two immuno-oncology agents in cancer...
1 October 2015 | By Victoria White
Secukinumab is the first interleukin-17A inhibitor to demonstrate efficacy in a Phase III study in patients with active psoriatic arthritis...
